Handling and patient preference of dry powder inhalers for asthma and COPD Source: Eur Respir J 2006; 28: Suppl. 50, 210s Year: 2006
Comparison of two dry powder inhalers containing budesonide in the treatment of asthma in children Source: Eur Respir J 2002; 20: Suppl. 38, 500s Year: 2002
Dose delivery characteristics of two dry powder inhalers in COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 291s Year: 2004
Applicability of dry powder inhalers in children with CF Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring Year: 2016
Efficacy and safety of salbutamol delivered via a novel multidose dry powder inhaler in comparison with two conventional dry powder inhalers and a pMDI in asthmatic subjects Source: Eur Respir J 2001; 18: Suppl. 33, 50s Year: 2001
Use of dry powder inhalers in COPD Source: Eur Respir J 2005; 26: Suppl. 49, 286s Year: 2005
Improving inhalation parameters through dry powder inhalers (DPIs) after an acute asthma exacerbation Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012
Do asthma patients achieve effective dosing from dry powder inhalers (DPIs)? Source: Eur Respir J 2005; 26: Suppl. 49, 338s Year: 2005
Effect of switching from salmeterol/fluticasone dry powder inhaler to formoterol/fluticasone pressurized metered-dose inhaler in elderly asthma patients Source: International Congress 2016 – Asthma management Year: 2016
Oral manifestations in asthmatic patients using metered dose inhaler and dry powder inhaler Source: International Congress 2019 – Innovations in primary care assessment and management Year: 2019
Clinical equivalence of budesonide delivered via two dry powder inhalers Source: Eur Respir J 2005; 26: Suppl. 49, 339s Year: 2005
The investigation of inhalation continuous duration for dry powder inhalers in asthmatic patients Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs Year: 2012
Formoterol delivered by multi-dose dry powder inhaler (MDDPI) improves nocturnal asthma symptoms Source: Eur Respir J 2005; 26: Suppl. 49, 50s Year: 2005
Carbon footprint of severe asthma exacerbation management relative to Breezhaler dry powder inhaler Source: Virtual Congress 2021 – Environment and respiratory health Year: 2021
One-year height growth in children with asthma treated with inhaled budesonide delivered from a new dry powder inhaler. Source: Annual Congress 2008 - Clinical aspects of asthma in school-aged children Year: 2008
Once-daily budesonide: clinical equivalence of two dry powder inhalers (DPIs) Source: Eur Respir J 2005; 26: Suppl. 49, 339s Year: 2005
Long-term preference and ease of use of a novel dry powder inhaler with budesonide in comparison to a conventional inhaler in asthmatic children Source: Eur Respir J 2001; 18: Suppl. 33, 121s Year: 2001
Reliability of inhalation therapy through a multidose dry powder inhaler Source: Annual Congress 2007 - Respiratory issues in primary care Year: 2007
A novel NEXT DPI® dry powder inhaler and its use in asthmatic and COPD population Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011
A study to evaluate the therapeutic equivalence of a new multidose budesonide dry powder inhaler with a conventional budesonide dry powder inhaler Source: Eur Respir J 2001; 18: Suppl. 33, 156s Year: 2001